In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis

被引:197
|
作者
Li, J
Turnidge, J
Milne, R
Nation, RL
Coulthard, K
机构
[1] Univ S Australia, Pharmaceut Res Ctr, Adelaide, SA 5001, Australia
[2] Womens & Childrens Hosp, Dept Infect Dis, Adelaide, SA, Australia
[3] Womens & Childrens Hosp, Dept Pharm, Adelaide, SA, Australia
关键词
D O I
10.1128/AAC.45.3.781-785.2001
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The in vitro pharmacodynamic properties of colistin and colistin methanesulfonate were investigated by studying the MICs, time-kill kinetics, and postantibiotic effect (PAE) against mucoid and nonmucoid strains of Pseudomonas aeruginosa isolated from patients with cystic fibrosis, Twenty-three clinical strains, including multiresistant strains, and one type strain were selected for MIC determination. Eleven strains were resistant; MICs for these strains were > 128 mg/liter, For the susceptible strains, MICs of colistin ranged from 1 to 4 mg/liter, while the MICs of colistin methanesulfonate were significantly higher and ranged from 4 to 16 mg/liter, The time-kill kinetics were investigated with three strains at drug concentrations ranging from 0.5 to 64 times the MIC. Colistin showed extremely rapid killing, resulting in complete elimination at the highest concentrations within 5 min, while colistin methanesulfonate killed more slowly, requiring a concentration of 16 times the MIC to achieve complete killing within 24 h, Colistin exhibited a significant PAE of 2 to 3 h at 16 times the MIC against the three strains after 15 min of exposure. For colistin methanesulfonate, PAEs were shorter at the concentrations tested. Colistin methanesulfonate had lower overall bactericidal and postantibiotic activities than colistin, even when adjusted for differences in MICs, Our data suggest that doses of colistin methanesulfonate higher than the recommended 2 to 3 mg/kg of body weight every 12 h may be required for the effective treatment of P. aeruginosa infections in cystic fibrosis patients.
引用
收藏
页码:781 / 785
页数:5
相关论文
共 50 条
  • [1] In vitro pharmacodynamic properties of colistin methanesulfonate and amikacin against Pseudomonas aeruginosa
    Bozkurt-Guzel, C.
    Gerceker, A. A.
    INDIAN JOURNAL OF MEDICAL MICROBIOLOGY, 2012, 30 (01) : 34 - 38
  • [2] Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa
    Bergen, Phillip J.
    Li, Jian
    Rayner, Craig R.
    Nation, Roger L.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (06) : 1953 - 1958
  • [3] In vitro activities of various antibiotics, alone and in combination with colistin methanesulfonate, against Pseudomonas aeruginosa strains isolated from cystic fibrosis patients
    Guezel, Cagla Bozkurt
    Gerceker, A. Alev
    CHEMOTHERAPY, 2008, 54 (02) : 147 - 151
  • [4] Pharmacokinetic/Pharmacodynamic Investigation of Colistin against Pseudomonas aeruginosa Using an In Vitro Model
    Bergen, Phillip J.
    Bulitta, Jurgen B.
    Forrest, Alan
    Tsuji, Brian T.
    Li, Jian
    Nation, Roger L.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (09) : 3783 - 3789
  • [5] Killing effect of nanoencapsulated colistin sulfate on Pseudomonas aeruginosa from cystic fibrosis patients
    Sans-Serramitjana, E.
    Fuste, E.
    Martinez-Garriga, B.
    Merlos, A.
    Pastor, M.
    Pedraz, J. L.
    Esquisabel, A.
    Bachiller, D.
    Vinuesa, T.
    Vinas, M.
    JOURNAL OF CYSTIC FIBROSIS, 2016, 15 (05) : 611 - 618
  • [6] Resistance to tobramycin and colistin in isolates of Pseudomonas aeruginosa from chronically colonized patients with cystic fibrosis under antimicrobial treatment
    Valenza, Giuseppe
    Radike, Kerstin
    Schoen, Christoph
    Horn, Stephan
    Oesterlein, Anett
    Frosch, Matthias
    Abele-Horn, Marianne
    Hebestreit, Helge
    SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 2010, 42 (11-12) : 885 - 889
  • [7] In vitro pharmacodynamics of ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients
    Manduru, M
    Mihm, LB
    White, RL
    Friedrich, LV
    Flume, PA
    Bosso, JA
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (09) : 2053 - 2056
  • [8] Patients with no cystic fibrosis bronchiectasis colonized by Pseudomonas aeruginosa: Role of inhaled colistin
    Ruiz, Abel Trujillano
    Ingles, Maria Jesus Aviles
    Lardon, Maria Teresa Antequera
    Miguel, Juan Jose Franco
    Martinez, Maria Carmen Abelian
    Martinez, Pedro Mendez
    Lopez, Jose Carlos Vicente
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [9] Colistin susceptibility testing: evaluation of reliability for cystic fibrosis isolates of Pseudomonas aeruginosa and Stenotrophomonas maltophilia
    Moskowitz, Samuel M.
    Garber, Elizabeth
    Chen, Yunhua
    Clock, Sarah A.
    Tabibi, Setareh
    Miller, Amanda K.
    Doctor, Michael
    Saiman, Lisa
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2010, 65 (07) : 1416 - 1423
  • [10] In Vitro Synergy of Colistin Combinations against Colistin-Resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae Isolates
    Vidaillac, Celine
    Benichou, Lothaire
    Duval, Raphael E.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (09) : 4856 - 4861